# A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct07755150` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07755150](<https://clinicaltrials.gov/study/NCT07755150>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07755150

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 272 participants.

## Technical summary

Registry record NCT07755150. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-30 (anticipated); primary completion 2027-10-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 272 participants (planned count; ClinicalTrials.gov record NCT07755150, source copy `cardio:ctgov-nct07755150-2026-08-31`, retrieved 2026-10-26)
- Planned start: 2026-08-30 (anticipated) (ClinicalTrials.gov record NCT07755150, source copy `cardio:ctgov-nct07755150-2026-08-31`, retrieved 2026-10-26)
- Primary completion: 2027-10-20 (anticipated) (ClinicalTrials.gov record NCT07755150, source copy `cardio:ctgov-nct07755150-2026-08-31`, retrieved 2026-10-26)
- Completion: 2027-10-20 (anticipated) (ClinicalTrials.gov record NCT07755150, source copy `cardio:ctgov-nct07755150-2026-08-31`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07755150, source copy `cardio:ctgov-nct07755150-2026-08-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07755150-2026-08-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): DA-302168S
- Intervention (Drug): Placebo of DA-302168S
- Lead sponsor: Chendu DIAO Pharmaceutical Group CO., LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: e1fe93027bf6320a615ae5cac293d1b59d5a5d5894418761be1e3eb4bfe5ad28
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
